Get the Stockscreener App
24.68
0.56%
-0.14
Pre-market:
25.02
0.34
+1.38%
Immunovant Inc stock is traded at $24.68, with a volume of 2.72M.
It is down -0.56% in the last 24 hours and up +53.10% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
See More
Previous Close:
$24.82
Open:
$24.88
24h Volume:
2.72M
Relative Volume:
1.63
Market Cap:
$4.30B
Revenue:
-
Net Income/Loss:
$-382.71M
P/E Ratio:
-9.4198
EPS:
-2.62
Net Cash Flow:
$-325.64M
1W Performance:
+30.31%
1M Performance:
+53.10%
6M Performance:
+52.82%
1Y Performance:
-15.65%
1-Day Range:
$24.49
$25.33
1-Week Range:
$19.21
$26.17
52-Week Range:
$12.72
$32.10
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
24.68 | 4.33B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | Truist | Hold |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Evaluating Immunovant (IMVT): Does Recent Momentum Signal a Premium Valuation? - Yahoo Finance
Will Immunovant Inc. stock outperform value stocksNew Guidance & Free Real-Time Volume Trigger Notifications - newser.com
How analysts rate Immunovant Inc. stock todayJuly 2025 Fed Impact & Consistent Profit Alerts - newser.com
Why Immunovant Inc. stock is popular among millennialsJuly 2025 Snapshot & Smart Allocation Stock Tips - newser.com
Can swing trading help recover from Immunovant Inc. lossesPortfolio Gains Report & Fast Entry Momentum Trade Alerts - newser.com
Analyzing net buyer seller activity in Immunovant Inc.July 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
Key resistance and support levels for Immunovant Inc.2025 EndofYear Setup & Stock Portfolio Risk Control - newser.com
Sentiment analysis tools applied to Immunovant Inc.July 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com
Is Immunovant Inc. stock oversold or undervaluedWeekly Market Report & Precise Entry and Exit Recommendations - newser.com
Will Immunovant Inc. stock go up soonQuarterly Profit Review & Risk Adjusted Buy and Sell Alerts - newser.com
Immunovant (NASDAQ:IMVT) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Immunovant: Takeover Buzz, IMVT-1402 Promise, And Why I'm Staying Neutral (NASDAQ:IMVT) - Seeking Alpha
Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results - Insider Monkey
How institutional ownership impacts Immunovant Inc. stockWeekly Profit Report & Safe Capital Growth Stock Tips - newser.com
Why analysts upgrade Immunovant Inc. stockJuly 2025 Market Mood & Precise Swing Trade Entry Alerts - newser.com
Immunovant gains amid takeover speculation (IMVT:NASDAQ) - Seeking Alpha
How to use Fibonacci retracement on Immunovant Inc.Portfolio Return Summary & Daily Profit Focused Screening - newser.com
IMMUNOVANT Earnings Preview: Recent $IMVT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Immunovant (NASDAQ:IMVT) Shares Up 7.8%What's Next? - MarketBeat
What sentiment indicators say about Immunovant Inc. stockBull Run & Breakout Confirmation Alerts - fcp.pa.gov.br
Graves ophthalmopathy treatment market is expected to reach US$ - openPR.com
What analysts say about Immunovant Inc stockDebt-to-Equity Ratio Analysis & Fast Growing Portfolio Trading - earlytimes.in
Can Immunovant Inc. stock continue upward trendJuly 2025 Summary & Growth Focused Entry Point Reports - Fundação Cultural do Pará
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 - The Manila Times
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):